Papillary thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, miR-146b-5p expression correlated with advanced PTC and promoted PTC development by targeting CCDC6 in vitro and in vivo; it could, therefore, serve as a promising target for PTC treatment.
|
30503553 |
2019 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PTC xenograft models were used to examine the effect of miR-146b-3p on PTC metastasis ability in vivo.
|
30244634 |
2018 |
Papillary thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Loss of DNA methylation is related to increased expression of miR-21 and miR-146b in papillary thyroid carcinoma.
|
30454026 |
2018 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggested the important roles of ITGA2, FN1, ICAM1, TIMP1 and CDH2 in the progression of PTC. miR-204-5p, miR-7-2, and miR-146b are potential biomarkers for PTC staging and FN1, CLDN1, and TNFRSF12A may serve as markers of prognosis in PTC.
|
30414611 |
2018 |
Papillary thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results indicated that the expression levels of serum miR-222, miR-221 and miR-146b were significantly increased in patients with newly diagnosed PTC compared with controls and patients with BTN.
|
28599426 |
2017 |
Papillary thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Based on our findings, the expression of miR-146a and miR-146b correlates with the occurrence and prognosis of papillary thyroid carcinoma, and the expression levels of miR-146a and miR-146b seem to affect the cell proliferation and migration and regulate the expression of IRAK1 protein in cancer cells.
|
29048684 |
2017 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conjunction with the current perspectives on miRNAs in a wide variety of human cancers, this review will hopefully translate these updated findings on miR-146b into more comprehensive diagnostic or prognostic information regarding treatment in PTC patients before surgical intervention and follow up strategies.
|
28294980 |
2017 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To test this hypothesis, we assessed the expression of RARB as well as miR-146a-5p and miR-146b-5p in 48 PTC tumor/normal tissue pairs by Taqman assay to reveal that the expression of RARB was 3.28-fold decreased, and miR-146b-5p was 28.9-fold increased in PTC tumors.
|
27011326 |
2016 |
Papillary thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression levels of miR-146b and IRAK1 of 50 cases of PTC and its adjacent normal thyroid specimens were assessed via qRT-PCR.
|
27533309 |
2016 |
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Relative expression of six microRNAs (miR-146b, -21, -221, -222, 375, -199b) appeared significantly different in BRAF(V600E)-positive samples (all classified as papillary thyroid carcinomas) compared to BRAF(V600E)-negative papillary carcinoma samples.
|
26960768 |
2016 |
Papillary thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we investigated whether miR-9, miR-10b, miR-21 and miR-146b levels are predictive of papillary thyroid carcinoma recurrence.
|
26007293 |
2015 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
For discrimination between benign and PTC lesions, the area under the ROC curve (AUC) for miR-146b was 0.649 with 61.4% sensitivity and 57.9% specificity.
|
25456009 |
2015 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To explore expression and clinical associations of miR-146a and miR-146b in papillary thyroid carcinoma.
|
25524940 |
2015 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent microRNA analysis revealed an association between miR146b and the BRAF mutation, which was associated with poor prognosis of papillary thyroid carcinoma (PTC).
|
25455162 |
2015 |
Papillary thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In order to examine the expression of miR-146b-5p and miR-21 in benign and malignant thyroid tissues and to determine if these microRNAs could be assigned to distinct histomorphological types of thyroid nodules, we analyzed miR-146b-5p and miR-21 expression in thyroid nodules on tissue microarrays (TMAs) with 193 thyroid specimens by ISH. miR-146b-5p and miR-21 expression in thyroid tissues was also analyzed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). miR-146b-5p was highly expressed (89%) in papillary thyroid carcinomas (PTCs) and 41% of FVPTC.
|
25771986 |
2015 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results showed that PTC cells overexpress miR-146b and miR-222 in exosomes; and that factors released by both normal thyroid and PTC cells alter proliferation of other cells in a complex manner.
|
25819770 |
2015 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that miR-146b-5p induces EMT and may promote PTC metastasis through the regulation of Wnt/β-catenin signaling, and suggest novel potential therapeutic targets for the treatment of PTC.
|
25547151 |
2015 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, our findings show that miR-146b and PAX8 regulate each other and share common target genes, thus highlighting a novel regulatory circuit that governs the differentiated phenotype of PTC.
|
26282166 |
2015 |
Papillary thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Eleven miRNAs were significantly differentially expressed between nodular goiter and PTC and between highly invasive and low invasive PTC. miR-199b-5p and miR-30a-3p were significantly differentially expressed among the three groups. miR-30a-3p, miR-122-5p, miR-136-5p, miR-146b-5p and miR-199b-5p were selected for further study by qRT-PCR and miR-146b-5p, miR-199b-5p and miR-30a-3p were different between the PTC and nodular goiter groups. miR-199b-5p was over-expressed in PTC patients with extrathyroidal invasion and cervical lymph node metastasis.
|
25100252 |
2014 |
Papillary thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MicroRNA-222 and miR-146b were over-expressed 10.8-fold and 8.9-fold, respectively, in Rc-PTC tumors compared with NR-PTC tumors (P = .014 and P = .038, respectively).
|
24301304 |
2013 |
Papillary thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Multivariate logistic regression analysis demonstrated advanced tumor stage, presence of cervical lymph node metastasis, and miR-146b expression were independent risk factors for poor prognosis in PTC.
|
23264400 |
2013 |
Papillary thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Significant miRNA deregulation was confirmed in the validation cohort, with upregulation of miR-146b-5p and miR-221/222 and downregulation of miR-16 and miR-613 in aggressive PTCs.
|
24064622 |
2013 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results confirm the oncogenic role of miR-146b-5p in thyroid follicular cells and contribute to knowledge regarding the modulation of TGF-β signal transduction by miRNAs in PTCs.
|
21874046 |
2012 |
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The analysis of miR-146b-5p and let-7f expression revealed a distinct pattern from a cohort of PTC patients, suggesting caution in evaluating miRNA expression data as molecular markers of PTC diagnosis and prognosis.
|
23295297 |
2012 |
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among BRAF-positive tumors, miR-146b showed strong association with aggressive PTC.
|
21537871 |
2011 |